July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent ...

Among high achievers are biopharmaceutical contract manufacturers in South Korea -- Samsung Biologics and Celltrion, both with strong first-half results.

Among high achievers are biopharmaceutical contract manufacturers in South Korea -- Samsung Biologics and Celltrion, both with strong first-half results.

AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA) ...

Celltrion announced on the 21st that its consolidated revenue in the second quarter of this year increased by 9.9% compared to the same period last year, amounting to about 961.5 billion won, and ...

Celltrion announced on the 23rd that it has donated 500 million won to the National Disaster Relief Association for those affected by the heavy rainfall. The funds will support emergency relief ...

Daewoong Pharmaceutical said Tuesday that it has decided to launch a biosimilar business as the Korean traditional drug maker looks for new growth engines. Daew ...

Celltrion, a major Korean biopharmaceutical firm, estimated that its second-quarter operating profit more than tripled from a year earlier on robust sales of high-margin biosimilar products.

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...